[ad_1]
Gytis Andrulionis, Head of the State Medicines Control Agency (IARC), Simona Stankevičiūtė, IWT Advisor and IUU Pharmacovigilance and Poisoning Information Unit, told us at a remote press conference about the vaccine, how it will work, which one is the beginning of its use and what are its possible side effects Rugilė Pilvinienė.
One dose will suffice
According to G. Andrulionis, this is the first vaccine that will be sufficient for one vaccination dose. It is based on adenovirus, as is AstraZeneca.
Gytis Andrulionis
“Preliminary delivery times are until the end of this year,” said the IWT head.
The first quantities of this vaccine will be symbolic. In total, Lithuania has decided to acquire 700 thousand. vaccine doses from this manufacturer.
Protection for at least three months
According to S. Stankevičiūtė, its operating principle is similar to that of AstraZeneca, but different from Pfizer and Moderna. The adenovirus vector in the vaccine, which is like a carrier, cannot really cause an infection because it is genetically modified.
According to S. Stankevičiūtė, this vaccine is still known to provide three months of protection against the coronavirus.
When it comes to vaccine efficacy, it is important to remember how this indicator is calculated.
“The efficacy of a vaccine is a relative measure and is not directly measured. If we say that the effectiveness of the vaccine is around 66%, it certainly does not mean that it is 66%. patients will not get sick and everyone else will not get sick in any way. We count how many events occurred among unvaccinated people, then we count how many events occurred in the population of those who were vaccinated. Subtract vaccinated from unvaccinated and divide unvaccinated, multiply by 100%. and we get the percentage of effectiveness of the vaccine, “said S. Stankevičiūtė.
In total, more than 19,000 people from the population whose vaccine was evaluated and who had been vaccinated were studied. Of those vaccinated, 116 developed COVID-19, or 0.59%. In the placebo group, the percentage was 1.76. The vaccine is estimated to be 66.4% effective.
“But overall, the vaccine’s effectiveness is about 66 percent. It’s similar across all age groups. In the clinical trial program, about 20 percent. People were over 65 and the results the efficacy of the vaccine are very similar, ”said S. Stankevičiūtė.
Without a doubt, the effectiveness of this vaccine is sufficient, otherwise it would not be registered in the European Union. About 20 percent. The patients were studied in South Africa, where the South African strain was prevalent. If the efficacy of the vaccine were less than any risk, it would not be recorded, ”said S. Stankevičiūtė.
Side effects similar to AstraZeneca
As Rugilė Pilvinienė, Senior Advisor to IWT’s Pharmacovigilance and Poisoning Information Unit, spoke at the press conference, given that the vaccine is similar in production to AstraZeneca, the side effects should also be similar. From what is stated in the SPC, the most common side effects are reactogenicity reactions.
These include headache, muscle pain, injection site pain, fatigue, and nausea. Serious reactions include anaphylactic shock. Since a single dose of this vaccine will suffice, it goes without saying that side effects occur after this dose.
It is not yet known how long the immunity will last, but it is expected to develop 14 days after vaccination.
It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to cite DELFI as the source. .
[ad_2]
